Difference between revisions of "Part:BBa K2549005:Design"

(→‎Design Notes)
m
 
(3 intermediate revisions by the same user not shown)
Line 2: Line 2:
 
__NOTOC__
 
__NOTOC__
 
<partinfo>BBa_K2549005 short</partinfo>
 
<partinfo>BBa_K2549005 short</partinfo>
−
 
 
<partinfo>BBa_K2549005 SequenceAndFeatures</partinfo>
 
<partinfo>BBa_K2549005 SequenceAndFeatures</partinfo>
  
  
 
===Design Notes===
 
===Design Notes===
−
Its heavy-chain variable region(&#945;CD19a) and light-chain variable region(&#945;CD19b) are fused using a glycine-rich peptide linker(3 repeats of GGGGS, or G4S)[1].
+
The heavy-chain variable region (&#945;CD19a) and light-chain variable region (&#945;CD19b) were fused together using a glycine-rich peptide linker (3 repeats of GGGGS, or G4S)<ref>Chimeric Antigen Receptor-Modified T Cells in Chronic Lymphoid Leukemia; Chimeric Antigen Receptor-Modified T Cells for Acute Lymphoid Leukemia; Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia. N Engl J Med, 2016 Mar;374(10):998  PMID: 26962747; DOI: 10.1056/NEJMx160005</ref>.
  
 
===Source===
 
===Source===
−
 
+
From IDT (gBlock), codon optimized for human
−
IDT(gBlock)
+
  
 
===References===
 
===References===
−
[1]Chimeric Antigen Receptor-Modified T Cells in Chronic Lymphoid Leukemia; Chimeric Antigen Receptor-Modified T Cells for Acute Lymphoid Leukemia; Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia.
 
−
.
 
−
N Engl J Med, 2016 Mar;374(10):998  PMID: 26962747; DOI: 10.1056/NEJMx160005
 

Latest revision as of 13:13, 12 October 2018


anti-CD19


Assembly Compatibility:
  • 10
    COMPATIBLE WITH RFC[10]
  • 12
    COMPATIBLE WITH RFC[12]
  • 21
    COMPATIBLE WITH RFC[21]
  • 23
    COMPATIBLE WITH RFC[23]
  • 25
    COMPATIBLE WITH RFC[25]
  • 1000
    INCOMPATIBLE WITH RFC[1000]
    Illegal BsaI site found at 444


Design Notes

The heavy-chain variable region (αCD19a) and light-chain variable region (αCD19b) were fused together using a glycine-rich peptide linker (3 repeats of GGGGS, or G4S)[1].

Source

From IDT (gBlock), codon optimized for human

References

  1. ↑ Chimeric Antigen Receptor-Modified T Cells in Chronic Lymphoid Leukemia; Chimeric Antigen Receptor-Modified T Cells for Acute Lymphoid Leukemia; Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia. N Engl J Med, 2016 Mar;374(10):998 PMID: 26962747; DOI: 10.1056/NEJMx160005